PT  - JOURNAL ARTICLE
AU  - Marguerite Thorp
AU  - MacDaphton Bellos
AU  - Tijana Temelkovska
AU  - Misheck Mphande
AU  - Morna Cornell
AU  - Julie Hubbard
AU  - Augustine Choko
AU  - Tom Coates
AU  - Risa Hoffman
AU  - Kathryn Dovel
TI  - Mobility and ART retention among men in Malawi: a mixed methods study
AID  - 10.1101/2022.11.07.22281938
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.11.07.22281938
4099  - http://medrxiv.org/content/early/2022/11/11/2022.11.07.22281938.short
4100  - http://medrxiv.org/content/early/2022/11/11/2022.11.07.22281938.full
AB  - Introduction Mobility is associated with worse outcomes across the HIV treatment cascade, especially among men. However, little is known about the mechanisms that link mobility and poor HIV outcomes and what types of mobility most increase the risk of treatment interruption among men in southern Africa.Methods From August 2021 – January 2022, we conducted a mixed-methods study with men living with HIV (MLHIV) but not currently receiving antiretroviral therapy (ART) in Malawi. Data collection was embedded within two larger trials (ENGAGE and IDEaL trials). We analyzed baseline survey data of 223 men enrolled in the trials who reported being mobile (defined as spending ≥14 nights away from home in the past 12 months) using descriptive statistics and logistic regression. We then recruited 32 men for in-depth interviews regarding their travel experiences and ART utilization. We analyzed qualitative data using constant comparative methods.Results Survey data showed that 34% of men with treatment interruptions were mobile, with a median of 60 nights away from home in the past 12 months; 69% of trips were for income generation. More nights away from home in the past 12 months and having fewer household assets were associated with longer periods out of care. In interviews, men reported that travel was often unplanned, and men were highly vulnerable to exploitive employer demands, which led to missed appointments and ART interruption. Men made major efforts to stay in care but were often unable to access care on short notice, were denied ART refills at non-home facilities, and/or were treated poorly by providers, creating substantial barriers to remaining in and returning to care. Men desired additional multi-month dispensing (MMD), the ability to refill treatment at any facility in Malawi, and streamlined pre-travel refills at home facilities.Conclusions Men prioritize ART and struggle with the trade-offs between their own health and providing for their families. Mobility is an essential livelihood strategy for MLHIV in Malawi, but it creates conflict with ART retention, largely due to inflexible health systems. Targeted counseling and peer support, access to ART services anywhere in country, and MMD may improve outcomes for mobile men.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study is supported by the Bill and Melinda Gates Foundation (INV-001423), the National Institute for Mental Health (R01-MH122308), and the UCLA Center for HIV Identification, Prevention and Treatment Services (P30MH058107). MT was supported by the National Institutes of Health (T32MH080634), and KD was supported by the Fogarty International Center (K01-TW011484-01) and UCLA GSTTP. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of the University of California Los Angeles gave ethical approval for this work ((#21-000209). IRB of the Malawi National Health Sciences Research Committee gave ethical approval for this work (#20/0712567).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to the sensitive nature of the data collected and the risk of unwanted disclosure of HIV status of participants, the data in this study will not be made routinely or publicly available. Some data produced in the study may be available upon request to the authors.ARTantiretroviral therapyENGAGEparent trialHCWhealthcare workerIDEaLparent trialIDIin-depth interviewMLHIVmen living with HIVPLHIVpeople living with HIVMMDmulti-month dispensingSSAsub-Saharan Africa